Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Llanos-González (Santa Cruz de Tenerife, Spain), J. Bordas Martínez (Barcelona, Spain), G. Bermudo Peloche (Barcelona, Spain), G. Suárez-Cuartín (Barcelona, Spain), V. Vicens Zygmunt (Barcelona, Spain), L. Planas-Cerezales (Barcelona, Spain), J. Palma López (Barcelona, Spain), L. Pérez Martín (Santa Cruz de Tenerife, Spain), R. Jodar Masanes (Barcelona, Spain), N. Padulles Zamora (Barcelona, Spain), S. García Gil (Santa Cruz de Tenerife, Spain), J. Dorca Sargatal (Barcelona, Spain), A. Medina Gonzálvez (Santa Cruz de Tenerife, Spain), O. Acosta Fernández (Santa Cruz de Tenerife, Spain), M. Molina Molina (Barcelona, Spain). Antifibrotic treatment in progressive non-IPF fibrotic interstitial lung diseases. 1731

Member's Comments

No comment yet.

Related content which might interest you: Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis Source: Eur Respir Rev, 28 (153) 190022; 10.1183/16000617.0022-2019 Year: 2019 Clubbing in patients with fibrotic interstitial lung diseases Source: International Congress 2017 – ILDs: clinical problems Year: 2017 Experience with antifibrotics treatment in progressive interstitial lung diseases non-IPF Source: Virtual Congress 2021 – Clinical evolution, management and outcomes of patients with rare diffuse parenchymal lung diseases Year: 2021 Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases Source: Eur Respir J, 54 (3) 1900161; 10.1183/13993003.00161-2019 Year: 2019 Treatment of progressive fibrosing interstitial lung diseases: a milestone in the management of interstitial lung diseases Source: Eur Respir Rev, 28 (153) 190109; 10.1183/16000617.0109-2019 Year: 2019 Clinical efficacy of pirfenidone in patients with severe fibrosing interstitial pneumonia Source: International Congress 2015 – Treatment of IPF Year: 2015 Rituximab in severe, treatment-refractory interstitial lung disease Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013 Nitrofurantoin-induced interstitial lung disease Source: Annual Congress 2012 - Viral infections and rare respiratory infections Year: 2012 Rituximab in severe, progressive interstitial lung disease Source: International Congress 2016 – Connective tissue disorders Year: 2016 Antifibrotics effects of nintedanib on lung fibroblasts derived from patients with progressive fibrosing intertitial lung diseases Source: Virtual Congress 2020 – Translational therapeutic advances Year: 2020 Genomic comparison of fibrotic rheumatoid arthritis-associated ILD and idiopathic pulmonary fibrosis Source: International Congress 2015 – Connective tissue disorders Year: 2015 Pertechnegas lung clearance in different forms of interstitial lung disease Source: Eur Respir J 2002; 19: 31-36 Year: 2002 Nintedanib in patients with chronic fibrosing interstitial lung diseases with progressive phenotype: the INBUILD trial Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Interstitial lung diseases and pulmonary hypertension Year: 2019 Aquoaporin-1 expression in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 Addition of respiratory hospitalizations 24weeks prior to the ILD-GAP model to predict mortality in chronic interstitial lung disease Source: International Congress 2016 – Clinical aspects of ILD Year: 2016 Nintedanib reduces fibrotic markers in the lung in a model of rheumatoid arthritis associated interstitial lung disease Source: International Congress 2016 – ILD pathogenesis Year: 2016 Occult connective tissue diseases mimicking idiopathic interstitial pneumonias Source: Eur Respir J 2008; 31: 11-20 Year: 2008 Interstitial fibrosis with a nodule Source: Annual Congress 2007 - Thoracic Oncology Grand Round: an interactive session Year: 2007 Using the ILD-GAP model to predict mortality in chronic interstitial lung disease Source: International Congress 2015 – IIPs: orphan Year: 2015